Clinical Trial Update: Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating teriflunomide plus high-dose dexamethasone as first-line therapy for newly diagnosed immune thrombocytopenia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Aubagio (teriflunomide) (teriflunomide)
• Decadron (Dexamethasone)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Immune Thrombocytopenia | Phase 2 | Status: WITHDRAWN